

JOINT EVENT ON

20th Euro-Global Summit on**Cancer Therapy & Radiation Oncology**
and**2nd International Oncologist & Diagnostics Conference**

August 28-30, 2017 Brussels, Belgium

Predictive value of PKM2 expression in advanced non-small cell lung cancer patients (NSCLC) treated with front-line platinum-based chemotherapy

Omnia Abd El-Fattah, Mohamed Sheta and Hanan A Alshenawy

Tanta University Hospital, Egypt

Background: The aim of the study was, to assess the expression of pyruvate kinase isozymes M2 (PKM2) in advanced NSCLC patients treated with front-line platinum-based chemotherapy and analyze its predictive value on both progression free and overall survival.

Methods: 72 cases with histologically confirmed stage IIIB and IV NSCLC who were treated with front-line platinum-based chemotherapy. 32 NSCLC patients were treated with front-line non-platinum-based doublets were enrolled in this study (as control), immunohistochemical staining for PKM2 was evaluated.

Results: In Platinum group, the median OS (overall survival) was 7 vs. 19 months; P 0.001 for those patients with high compared to those with low expression respectively and the median PFS was 5 vs. 9 months; P 0.001 for those patients with high PKM2 expression compared to those with low expression respectively. In control group, there was no significant difference between high and low PKM2 expression as regard median OS (9 vs 10 months; $P \leq 0.451$) and median PFS progression-free survival (7 vs. 8 months; $P = 0.638$).

Conclusions: Our study proved that PKM2 expression may be a predictive biomarker of platinum sensitivity in advanced NSCLC patients treated with platinum-based chemotherapy.

Biography

Omnia Abd El-Fattah is an Assistant Professor of Clinical Oncology, Faculty of Medicine Tanta University Hospital, Egypt, member of the Egyptian Association for Cancer-based National Cancer Institute, Cairo, Egypt and Patients' Friends Society tumors in Gharbia based Department for Clinical Oncology, Tanta University Hospital, Egypt. She has Master's and MD degrees in Clinical Oncology in 2002 and 2009 respectively from Faculty of Medicine Tanta University Hospital, Egypt. Her Master's and MD theses focused on non-Hodgkin's lymphomas. She is teaching postgraduate students and is interested in participating in a therapeutic service in university hospitals. She attended many courses in the capabilities of faculty development and supervised multiple Master's and MD theses. She has attended multiple national and local conferences of Clinical Oncology and has multiple international published papers in Clinical Oncology.

omniaabdefattah@yahoo.com

Notes: